Translated from Romanian

Page 1 of 2 to English - www.onlinedoctranslator.com F01-PG21 Ed.6,Rev.0 20/03/2023 16:31:45

ANALYSIS BULLETIN NO. 23317T1267 of 03/17/2023

(09009)Bioclinica Iasi <-- (09009)Bioclinica Iasi, collected: 16/03/2023 09:54, worked: Bioclinica SA, Medical analysis laboratory, Timisoara, B-dul Cetatii, No. 53B 23316I7319
(00015)Bioclinica Nicolina

DULAN RODICA, 23 years old, F, IS, Iasi, CNP: 2990323373971 , phone: 0756851669
Sent by: doctor PAVALEANU IOANA
================================================== ====================VAL.BIOL.REF.====================ANTECEDENT=========

Genetic profile of thrombophilia risk...

Factor V G1691A (Leiden) mutation absent

Factor V H1299R (R2) mutation absent

Factor II G20210A heterozygous mutant

MTHFR C677T heterozygous mutant

MTHFR A1298C heterozygous mutant

Factor XIII V34L heterozygous mutant

PAI-1 5G/5G homozygous

EPCR present alleles A1/A1

Factor II (Prothrombin, PTH) G20210A - mutation is associated with increased

prothrombin levels. Carriers have a 3 times higher risk for cerebral and deep
vein thrombosis. The risk increases significantly in association with factor V
Leiden.

MTHFR C677T - the heterozygous mutation is associated with a reduction in the

enzymatic activity of methylenetetrahydrofolate reductase, an increase in the
plasma level of homocysteine, in association with folate deficiency.

MTHFR A1298C - the mutation is involved in decreasing the enzymatic activity of

methylenetetrahydrofolate reductase (MTHFR). The associated heterozygous
variants of MTHFR C677T and A1298C are considered a cardiovascular risk factor.

Factor XIII V34L - the mutation provides protection against venous

thromboembolism.

* It is recommended that in certain circumstances (surgical interventions,

fractures, administration of oral contraceptives, pregnancy, etc.) the results of
these analyzes be communicated to the attending physician.

(whole blood EDTA, PCR & Reverse Hybridization)

The results refer only to the analyzed sample. The total or partial reproduction of the analysis report is made only with the agreement of "BIOCLINICA."
Page 2 of 2 F01-PG21 Ed.6,Rev.0 20/03/2023 16:31:45

ANALYSIS BULLETIN NO. 23317T1267 of 03/17/2023

(09009)Bioclinica Iasi <-- (09009)Bioclinica Iasi, collected: 16/03/2023 09:54, worked: Bioclinica SA, Medical analysis laboratory, Timisoara, B-dul Cetatii, No. 53B 23316I7319
(00015)Bioclinica Nicolina

DULAN RODICA, 23 years old, F, IS, Iasi, CNP: 2990323373971 , phone: 0756851669
Sent by: doctor PAVALEANU IOANA
================================================== ====================VAL.BIOL.REF.====================ANTECEDENT=========

Homocysteine...
6.58 µmol/L (< 10.00)
0.89 mg/L (< 1.35)

Interpretation:
µmol/L (mg/L)
Ideal level ............ < Acceptable 10.00 (< 1.35)
level ....... Hyperhomocysteinemia 10.00 - 15.00 (1.35 - 2.03)

moderate ......... > 15.00 - 30.00 (> 2.04 - 4.05)

intermediate ..... > 30.00 - 100.00 (> 4.06 - 13.50)
severe ........... > 100.00 (> 13.50)

(EDTA plasma, HPLC)

Needle panel. anti nuclear antigens (ANA) IgG...

===VAL.BIOL.REF.===
Needle. anti nRNP/Sm................... Negative Ac. anti (Negative)
Sm.................... Negative Ac. anti SS-A (Ro-60)............. (Negative)
Negative Ac. anti Ro-52................... Negative Ac. anti SS-B (Negative)
(La)................ Negative Ac. anti Scl-70................... Negative (Negative)
Ac. anti PM-Scl 100............... Negative Ac. anti (Negative)
Jo-1..................... Negative Ac. anti Centromere B.............. (Negative)
Negative Ac. anti PCNA..................... Negative Ac. anti (Negative)
dsDNA................... Negative Ac. anti (Negative)
Nucleosome................ Negative Ac. anti (Negative)
Histone................... Negative Ac. anti Ribosomal Protein (Negative)
P.... Negative Ac. anti AMA-M2................... Negative Ac. (Negative)
anti DFS70................... Negative (Negative)
(Negative)
(Negative)
(Negative)
(Negative)

(serum, Line blot)

Analyzes and collection points marked (#) are NOT covered by RENAR accreditation.
For additional details, please request the accreditation certificate at timisoara@bioclinica.ro. Opinions
and interpretations are not covered by RENAR accreditation.
================================================== ================================================== ======================

The results refer only to the analyzed sample. The total or partial reproduction of the analysis report is made only with the agreement of "BIOCLINICA."